MedTrace Logo

Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome

NCT02022228 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-12-27

No results posted yet for this study

Summary

Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients.

However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.

Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.

Conditions

  • Infertility and at High Risk of OHSS

Interventions

DRUG

triptorelin

0.2 mg triptorelin, ih

DRUG

hCG

1000 IU hCG, im

DRUG

hCG

500IU hCG, im

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Comprehensive Strategic Cooperation Project of Guangdong Province and Chinese Academy of Science

    collaborator OTHER

  • Guangzhou Science and Technology Program key projects

    collaborator OTHER

  • National Key Basic Research Development Plan of China

    collaborator UNKNOWN

  • Chenshiling

    lead OTHER

Principal Investigators

  • Shi-Ling Chen, M.D., Ph.D. · Nanfang Hospital, Southern Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-12-31
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022228 on ClinicalTrials.gov